Co-reported respiratory adverse events in trastuzumab deruxtecan–associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database
Journal of Oncology Pharmacy Practice
Published online on April 16, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundTrastuzumab deruxtecan (T-DXd) is an effective HER2-directed antibody–drug conjugate used across multiple solid tumors. Interstitial lung disease (ILD) and pneumonitis are well-recognized as clinically significant toxicities associated with T-...
BackgroundTrastuzumab deruxtecan (T-DXd) is an effective HER2-directed antibody–drug conjugate used across multiple solid tumors. Interstitial lung disease (ILD) and pneumonitis are well-recognized as clinically significant toxicities associated with T-...